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The genetics of asthma 
S. HOLGATE 
University of Southampton, Tremona Road, Southampton, SO16 6YD, U.K. 
Asthma is a complex disorder in which many genes are involved. One major problem is the definition of the phenotype and 
how to make best use of questionnaire, physiological and laboratory measures. The development of quantitative traits based 
on scores derived from integrating a number of separate variables provides a robust method for use in linkage and association 
studies. Thus, using the approach applied to 360 families, we have shown strong evidence for linkage to chromosome 12q and 
5q, independent of atopy, regions containing both well recognized and novel genes of interest. 
Association studies have also proven to be powerful methods for investigating the role of individual mutations to either a 
complex disease phenotype or a subphenotype. Candidate genes involving IL-4 and IL-13 with their corresponding receptors 
and the cysleinyl leukotriene generating pathway are of special interest in asthma. Data will be presented revealing the 
importance of these pathways and how genetic variations influence their expression in relation to disease. 
Taking advantage of the unique immunopathology of asthma, we have used differential cloning to identify both novel and 
well recognized genes that are expressed in atopic asthma compared to atopic normal airway biopsies. A further approach 
has been to use Atlasa array to identify novel cellular mechanisms that are over or under expressed in epithelial cells in 
normal and asthmatic airways. These studies have revealed key metabolic pathways in the airway epithelium that are 
disordered (up or down regulated) in asthma. This has helped take the focus away from this disease as being purely a 
disorder of ThZ/Thl polarisation. Of particular significance is the role of oxidant/antioxidant pathways and the epithelial- 
mesenchyme trophic unit both of which are altered in asthma and also pivotal to normal airway growth and branching 
during morphogenesis. 
Asthma genetics will only deliver when novel abnormalities can be translated to functional impairments that are relevant to 
the human disease. The next few years will prove especially exciting as these conneclions start to be made. 
The genetics of emphysema/COPD 
R. A. STOCKLEY 
University Hospital Birmingham, Edgbaston, Birmingham B15 2TH, U.K. 
It is a generally accepted concept that although cigarette smoking is associated with the development of chronic obstructive 
pulmonary disease (COPD) the majority of smokers appear relatively immune. This suggests that there are factors that 
determine the susceptability of individuals to the destructive processes related to cigarette smoking. Family studies have 
shown that the development of airflow obstruction can effect several members. This may reflect a true genetic susceptibility as 
well as other social and environmental factors. However, several epidemiological studies have confirmed (controlling for 
environmental factors) that relatives of patients with airflow obstruction are more likely to have a decrease in their lung 
function compared to matched unrelated controls. 
The first specific genetic cause to be identified was alpha-1-antitrypsin deficiency. This was first described in 1963 and early 
studies indicated that the majority of individuals who smoked developed severe early onset COPD and died at a young age. 
However, other studies of patients with this deficiency have indicated that airflow obstruction can run through the family 
irrespective of alpha-I-antitrypsin phenotype. In addition, the majority of subjects with alpha-l antitrypsin deficiency have yet 
to be identified indicating that they do not present to the healthcare system. The implications of this are that the majority 
remain reasonably well. It is therefore possible that even alpha-1-antitrypsin deficiency is not a true genetic factor, but a 
secondary factor that highlights the severity of the development of COPD. 
In recent years further genetic studies have indicated that conditions like cutis laxa are also associated with the development 
of COPD and other genetic studies of alpha-I-antitrypsin gene (Taq 1 polymorphism)? the TNF gene and the epoxide 
hydrolase gene have all indicated that these are over represented in groups of patients with COPD compared to controlled 
populations. The implication of these findings is as yet unknown and further studies will be necessary to determine their true 
influence on the development of disease. 
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Molecular genetics of interstitial lung disease 
R. M. DU BOIS 
Royal Brompton Hospital, Sydney Street, London SW3 6NP, U.K. 
There are over 200 specific diffuse lung diseases. The aetiology of some of these is known whereas for others it is not. 
Increasingly however, it has been recognised that exposure to agents known to cause diffuse lung disease affects only a 
proportion of the population, suggesting that there may exist predisposing genetic factors. It is clear that the patterns of 
genetic predisposition are not simple but complex, likely involving a number of distinct genetic loci. There are two broad 
approaches to the question of genetic predisposition: genotyping families of individuals in whom the disease occurs in more 
than one person; or, by using a case-referent strategy directed against candidate genes identified from a knowledge of the key 
components in pathogenesis. 
In most diffuse lung diseases there are few affected families. This means that the main approach has been a candidate gene 
strategy. Using this strategy, we have identified a number of loci that appear to increase the risk of developing sarcoidosis and 
fibrosing alveolitis in the context of systemic sclerosis. More disappointing are the results of studies of cryptogenic fibrosing 
alveolitis. 
In sarcoidosis the loci of interest are 
1. Class II MHC genes, particularly HLA-DR and DP alleles 
2. Genes associated with antigen processing, notably TAP genes 
3. Angiotensin Converting Enzyme polymorphisms 
In systemic sclerosis, it is becoming clear that the major determinant of clinical phenotype is the autoantibody profile: the 
anti-topoisomerase autoantibody, Scl 70 is associated with internal organ, particularly pulmonary fibrosis; the anti- 
centromere antibody with vascular disease; the anti-ribonuclear protein antibody with renal disease and the polymyositis-anti- 
topoisomerase antibody (PM/Scl) with scleroderma/polymyositis overlap. Recent data have shown a strong HLA-DP 
association with Scl70, suggesting that the autoantibody profile and, thus, clinical phenotype is under genetic modulation. To 
date, the only genetic association with cryptogenic fibrosing alveolitis that has been reported is a polymorphism in the 
interleukin-1 receptor antagonist gene. Future approaches, in the absence of large family cohorts, will require a co-ordinated, 
collaborative strategy. 
The genetics of pulmonary hypertension 
N. W. MORRELL 
Section of Clinical Pharmacology, Division of Medicine, Imperial College School of Medicine, Hammersmith 
Hospital, Du Cane Road, London W12 ONN, U.K. 
Pulmonary arterial hypertension usually occurs secondary to chronic heart or lung disease, or much more rarely as a primary 
condition with no obvious underlying cause. One of the most important causes of pulmonary hypertension in patients 
with lung disease is pulmonary vasoconstriction in response to alveolar hypoxia, with eventual structural remodelling of 
the pulmonary circulation, leading to a relatively fixed elevation of pulmonary vascular resistance. There is considerable 
interindividual variation in the magnitude of the hypoxic pulmonary vasoconstrictor response in normal subjects, and in the 
susceptibility of patients to hypoxic pulmonary hypertension. A genetic basis to this susceptibility is suggested by observations 
in animal models. Some strains of cattle are prone to right heart failure (‘brisket disease’) at high attitude, a trait which was 
shown to be transmitted to the offspring of affected parents. We have identified two strains of rat with differing susceptibilities 
to hypoxia-induced pulmonary hypertension. Cross breeding studies have suggested that this susceptibility may be under the 
control of one or two genes. Our group has identified a quantitative trait locus associated with the increased susceptibility to 
right ventricular hypertrophy in the susceptible strain. In order to identify the genetic basis of hypoxia-induced pulmonary 
hypertension in man, we are studying individuals with high altitude pulmonary hypertension (HAPH) living in the Tien-Shan 
and Pamir mountain ranges of Kyrghyzstan. As part of a candidate gene approach, we found that individuals susceptible to 
HAPH were six times more likely to carry the II genotype of a polymorphism in the angiotensin converting enzyme (ACE) 
gene, compared with highland residents with no pulmonary hypertension. Our recent studies have established that 
susceptibility to pulmonary hypertension segregates within families in these high altitude residents. Primary or unexplained 
pulmonary hypertension is familial in 6% of cases. The condition has an autosomal dominant pattern of inheritance with 
incomplete penetrance, and exhibits genetic anticipation. The gene for familial primary pulmonary hypertension was recently 
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localized to the long arm of chromosome 2. The identification of candidate genes involved in the pathogenesis of hypoxia- 
induced or primary pulmonary hypertension will lead to a greater understanding of pulmonary vascular biology and enable 
the development of new therapeutic targets in the treatment of these conditions. 
ytokine gene transfer in models of pulmonary inflammation 
J. GAULDIE”, I? J. SIME?, R. MARR” AND Z. XING* 
“Centre fey Gene Therapeutics, Department of Pathology and Molecular Medicine, Men/laster University, 
Hamilton, Ontario, L8N 325 Canada and 
+Division of Respiratory Medicine, University of Edinburgh, U.K. 
Many cytokines have been implicated as important soluble signalling molecules that dictate and co-ordinate inflammatory 
and immune responses in pulmonary tissues. A number have been implicated in the pathogenesis of chronic fibrotic diseases, 
such as the early phase inflammatory cytokines, IL-l and TNFa, members of the chemokine families; including IL-8 and 
MCP-1, and growth and differentiating factors such as PDGF, FGF and TGFfi. All are implicated in fibrogenesis through 
their putative mode of action and demonstrated presence in fibrotic tissue. Most data implicating these factors are derived 
from in vitro studies with limited data available from administration of recombinant material in vivo, due to the short half-life 
of most of these mediators. 
To mimic the conditions related to a prolonged inflammatory response, thought to be a relevant precursor to fibrogenesis, 
we have developed a series of replication deficient recombinant Adenovirus vectors (Ad) with incorporated cytokine genes. 
These can be used to transfer the gene(s) of interest to the lung, and result in transient (7-10 day) overexpression of the 
cytokine within the pulmonary tissue. The gene is expressed at high levels within 24 h of administration, both within the lumen 
of the lung and within the parenchymal tissue. 
Examination of a number of individual cytokines shows that while many will initiate acute pathologic changes within the 
lung, such as the accumulation of neutrophils (AdIL-8) or mononuclear cells (Ad IP-10) or both (Ad TNF), most do not cause 
extended tissue damage or remodelling. Only if the cytokine expression leads to the generation of significant endogenous 
TGFj3 levels or if the active form of TGFP is transferred directly do we see the induction of a progressive fibrogenic process. 
These studies implicate TGFB as a critical factor in fibrogenesis in vivo and suggest that targeting active TGFP, or the 
activating process itself, or genes downstream of TGFP signalling, will be important in developing therapeutic interventions to 
inhibit fibrogenesis and reverse the distored tissue remodelling associated with idiopathic pulmonary fibrosis. 
Supported by MRC Canada, Hamilton HSC and St Joseph’s Hospital 
The use of transgenic models to study pathogenic 
mechanisms in asthma 
Yale University School of Medicine, New Haven, CT 06520 8057, U.S.A. 
Asthma is a chronic inflammatory disorder involving the airways. We have traditionally thought of asthma as an entirely 
reversible disease. Recent studies, however, suggest that asthmatics experience accelerated rates of respiratory deteriora- 
tion and that the reversibility in asthmatic airways, in some patients, can be diminished over time. It has been proposed 
that the chronic inflammatory changes in asthmatic airways result in structural alterations termed airway remodelling and 
that these alterations contribute to the pathogenesis of the manifestations of the asthmatic diathesis. This response 
includes mucus metaplasia, subepithelial fibrosis, myocyte hyperlasia and hypertrophy, myofibroblast hyperplasia and airway 
wall thickening. This talk will discuss the importance of airway remodelling as a pathological entity and pathogenetic 
construct. 
In addition, investigations of the pathogenesis of airway remodelling using overexpression transgenic approaches targeting 
IL-11 and IL-13 to the airway will be described. These studies demonstrate that IL-11 induces subepithelial fibrosis 
characterized by the enhanced accumulation of types I and III collagen and myocyte and myofibroblast hyperplasia. It also 
caused airways obstruction and airways hyper-responsiveness on agonist challenge. In contrast, the overexpression of IL-13 
caused a lymphocytic and eosinophilic inflammatory response that is associated with subepithelial fibrosis, mucus metaplasia 
and mucus hypersecretion, airways obstruction and airways hyper-responsiveness on methacholine challenge. 
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Human gene therapy: cystic fibrosis 
E. ALTON 
Gene Therapy Unit, Imperial College, London, SW3 6LR, U.K. 
Following the generation of cystic fibrosis (CF) mice, we demonstrated that these animals showed the electrophysiological 
abnormalities characteristic of this disease. We subsequently showed that transfer of a normal copy of the CF gene into CF 
mice could correct this abnormality. This led to the first trial of liposome-mediated gene transfer in the nasal epithelium of CF 
subjects. Both these studies demonstrated safety and proof of concept that gene therapy is a viable proposition. We completed 
the first liposome-mediated trial of gene therapy in the lungs of CF subjects demonstrating a small, but significant 
improvement in chloride transport in this key target organ. As a result of these CF studies, gene therapy for lung cancer, 
chronic lung inflammation and pulmonary oedema are being pursued in the laboratory. In parallel an extensive programme of 
laboratory work aimed at improving gene transfer efficiency is being undertaken. 
The therapeutic potential of antisense oligonucleotides 
F. E. COTTER 
Experimental Haematology, St Bartholomew‘s and The Royal London School of Medicine, Turner Street, London 
EI 2AD U.K. 
Irretrievably damaged cells, cancerous or not, commit suicide by apoptosis. Chemotherapy triggers the cascade of genetically 
programmed molecular events that ends in shredding repair proteins, structural proteins and genetic material. However, if a 
mutation blocks any point on this cascade, chemotherapy fails. The ability to pharmacologically regulate gene expression by 
antisense obligonucleotides (ASO) represents a potentially powerful therapeutic strategy. We are interested in the in vivo 
artificial supression of anti-apoptosis oncogenes, such as BCL-2, which are overexpressed in follicular lymphoma (bearing the 
t(14;18) q32;q21 translocation), and childhood acute leukaemia (bearing t(14;11)(q21;q23) translocation). This group of 
proteins, known to be increased in many other malignancies, contributes to a chemoresistant phenotype. Our aim is to 
develop and accurately assay the oncoprotein reducing and chemosensitizing potencies of novel antisense agents using 
rigorous quantitative techniques, and transfer selected effective agents into the clinic. Our group has previously demonstrated 
BCL-2 AS0 efficacy in a murine SCID-human xenotransplantation model. We are currently conducting a phase I study of an 
antisense molecule that binds to messenger RNA encoding the death-inhibiting Bcl-2 protein. Ultimately, antisense therapy 
will be combined with chemotherapy, which is expected to increase efficacy as compared to either treatment alone. 
BALR Young Scientist Competition 
Characterization of the interaction of mast cell tryptase with 
protease-activated receptor-2 (PAR-2) on human lung 
fibroblasts 
I. A. AKERS*, G. J. LAURENT*, S. SANJAR? AND R. J. MC Andy* 
“Centre for Cardiopulmonary Biochemistry and Respiratory Medicine, Royal Free and University College 
Medical School, 5 University Street, London WCIE 6JJ and t Glaxo Wellcome R&D Ltd, Medicines Research 
Centre, Gunnels Wood Road, Stevenage, Herts, SG12 2NY, U.K. 
Protease activated receptor-2 (PAR-2), a 7 transmembrane G protein-linked receptor, has been localized to many cells in 
the lung, including fibroblasts and myofibroblasts and its activation induces proliferation in these cells. Increased numbers 
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of fibroblasts and activated mast cells are associated with tissue remodelling in the lungs of patients with asthma, chronic 
obstructive lung disease and lung fibrosis. We have previously presented data suggesting the mast cell protease, tryptase, 
induces lung fibroplast proliferation via activation of PAR-2. We have extended these observations by examining the time- 
course of tryptase-induced proliferation and the role of PAR-2 in mediating the effects of tryptase on human foetal lung 
fibroblasts using a rabbit anti-rat PAR-2 polyclonal antisera (B5). Lung fibroblasts were exposed to tryptase for varying 
lengths of time, up to 48 h, after which the agonist was removed and proliferation examined after a total incubation time of 
48 h. In blocking studies, cells were preincubated with PAR-2 antisera (1:2000 dilution) for 1 h prior to treatment with 
tryptase or the known PAR-2 agonist, trypsin. Data are expressed as percentage increases in cell number compared with 
cells grown in media alone. In the time course studies, tryptase (17 mU ml-‘) caused proliferation after only 5 min exposure 
(38.0+ 1.4%; P<O.Ol) with a further increase in proliferation after 24 h incubation (65.6$3,7%). After 48 h treatment, 
tryptase (17 mU ml-‘) and trypsin (10 nM) increased fibroblast cell numbers by 75.6 + 2.8% and 34.5 i 3.7% respectively 
(P~0.01). Preincubation of the cell cultures with the PAR-2 antisera completely inhibited the effects of trypsin 
(lOOf 17,5%, P<O.Ol), whereas it only partially inhibited the effects of tryptase (63.3$4,1%, P~0.01). Partial inhibition 
was also observed when cells were incubated with tryptase for 5 min and 24 h (44.9* 11.4%; 358+9.9%), respectively, 
P<O.Ol). These studies show for the first time that blocking the activation of PAR-2 with neutralizing antibodies can 
inhibit the mitogenic effects of trypsin, and partially inhibit the effects of tryptase. These data demonstrate that the 
mitogenic effects tryptase are at least partly mediated via activation of PAR-2, however additional mechanisms may also be 
involved. 
This work was supported by Glaxo Wellcome R&D Ltd. 
Reaction of diesel exhaust particles and soluble surface 
components with alveolar type II and 
type I-like cells in vitro 
L. J. REYNOLDS *, S. MURPHY*, M. MCELROY+ AND R. J. RICHARDS* 
*School of Biosciences, Cardiff University, POBox 911, Cavdiff CFl 3US and +Rayne Laboratories, University of 
Edinburgh, Teviot Place, Edinburgh, EH8 9AG, U.K. 
Diesel exhaust particles (DEP) can form a major constituent of airborn particulate matter in cities. Individual particles 
are 20 nm in diameter, although they readily aggregate and have a disordered carbon structure containing 
heterogeneous distribution of metal contaminants (Berube et al. Atmos Environ 1999: 33; 1599). The objective of this 
study was to determine the bioreactivity of DEP, before and after washing soluble components from the particles 
surface. 
EXPERIMENTAL 
The response of type II cells in culture to full DEP, washed DEP and supernatant was examined. The responses were 
characterized through the dose required to kill half the cells (TD50), analysed with cell number, cell protein, gamma glutamyl 
transpeptidase (type II cell marker) and rTIdO ( a type I cell marker-Dobbs et al. Biochem et Biophys Acta 1988: 970; 146- 
156). Washed DEP was produced by sonication of full DEP for 1 h followed by pelleting at 550 g for 1 h. Full DEP, washed 
DEP and the supernatant from pelleting washed DEP, were added to 200 000 type II cells/96 well at concentrations ranging 
from O-200 pg well-‘. The three forms of diesel preparations were added to freshly isolated cells, 48 h type II cells and 144 h 
type I-like cells. 
RESULTS 
The type II and type I-like cells proved to be resilient to DEP. The toxicity of the full and washed DEP was similar suggesting 
that removing soluble surface components from the particle does not reduce toxicity. However, there were bioreactive 
components in the concentrated fraction of the soluble surface material. 
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Deficiency in TGF$ Induced PGE2 synthesis in fibroblasts 
isolated from patients with pulmonary fibrosis is due to a 
failure to upregulate COX-2 expression 
C. B. KEERTHISINGAM*, M. L. FOSTER?, G. J. LAURENT* AND R. J. MCANULTY* 
“Centre for Cardiopulmonary Biochemistry and Respiratory Medicine, Royal Free and University College 
Medical School, London, WCZE 6JJ, UK and +Discovery Biology, Rhone-Poulenc Rover Dagenham, RMIO 7XS, 
U.K. 
Enhanced fibroblast proliferation and collagen synthesis are two key events in the pathogenesis of pulmonary fibrosis. The 
paracrine hormone, prostaglandin E2 (PGEJ is a potent inhibitor of these processes and patients with pulmonary fibrosis 
demonstrate reduced levels of this mediator. Synthesis of PGE2 by fibroblasts is induced by profibrotic mediators such as 
transforming growth factor-beta (TGF-P) and modulates its effects on fibroblast proliferation and collagen synthesis. We 
have previously demonstrated that fibroblasts isolated from patients with pulmonary fibrosis lack the anti-proliferative 
response to TGF-pI and exhibit enhanced collagen synthesis. In this study we measured basal and TGF-flI induced PGE2 
synthesis (pg/ml) in fibroblasts derived from normal and fibrotic lung, presented as the median and range. Further, we 
determined the role of cyclooxygenase 2 (COX-2) by selective inhibition of enzyme activity and analysis of mRNA. Under 
basal conditions normal fibroblasts (n=6) synthesized more PGE2 than fibroblasts from fibrotic lung (n=6) [normal 381 
pm-‘, range 31-2720 pg ml-’ fibrosis 46 pg ml-‘, range 24-126 pg ml-‘, P-cO.051. . When stimulated with TGF-P1 
(1 ng ml-‘), fibroblasts from fibrotic lung synthesized less PGE2 than normal fibroblasts [normal 767 pg ml-‘, range 410- 
3200 pg ml-*; fibrosis 94 pg ml-‘, range 50-370 pg ml-‘; P<O.O5]. The selective COX-2 inhibitor, NS-398 (15 pg ml-‘) 
inhibited TGF-fil induced PGEz synthesis in fibroblasts from both normal and fibrotic lung (normal 94% i 6 inhibition; 
fibrosis 98% + 1 inhibition; P<O.OOl). In contrast, a preferential inhibition for cyclooxygenase-1 (COX-I), piroxicam (2.5 ng 
ml-‘) had no significant effect. Analysis of steady state mRNA levels demonstrated abundant COX-1 mRNA in fibroblasts 
from normal and fibrotic lung which did not change in the presence of TGF-PI. However, basal COX-2 mRNA was low but 
detectable and was upregulated by TGF-Pl in normal fibroblasts but not in fibroblasts isolated from fibrotic lung. Taken 
together these results suggest that TGF-P1 induced PGEz synthesis is mediated by COX-2 in normal lung fibroblasts and the 
failure to increase PGEz synthesis in fibroblasts from fibrotic lung may be attributable to an inability to sufficiently upregulate 
COX-2 gene expression. 
This work was supported by the BBSRC and Rhone-Poulenc Rorer 
Free Communications 
Role of matrilysin in repair of epithelial injury in the Lung 
S. E. DUNSMORE X. YE. L. Yin, J. D. ROBY, C. L. WILSON, H. G. WELGUS AND WILLIAM C. 
PARKS 
Washington University School of Medicine, St. Louis, MO, U.S.A. 
Matrix metalloproteinases (MMPs) are involved in a variety of normal and pathological processes including wound repair. 
We are interested in the role of MMPs in acute lung injury and have previously demonstrated that matrilysin, the smallest 
known MMP, is prominently expressed by airway and alveolar epithelial cells in damaged lungs (Dunsmore et al., J. Clin 
Invest 1998: 102, 1321). Following lung injury, type II pulmonary epithelial cells undergo a process which involves 
proliferation, migration and differentiation to restore a functional alveolar epithelial barrier. The present studies were 
designed to examine the role of matrilysin in type II cell migration. In specimens of diffuse alveolar damage and interstitial 
pneumonitis, matrilysin was prominently expressed by alveolar epithelial cells. Matrilysin-positive pneumocytes were 
frequently found in areas adjacent to denuded alveolar basement membrane, suggesting that matrilysin may function in 
facilitating cell migration. In two different in vitro assays, migration of A549 cells, a human cell line with type II cell 
characteristics, to fibronectin was inhibited by more than 60% by treatment with a broad spectrum peptide hydroxamate 
metalloproteinase inhibitor. Migration to fibronectin was also substantially impaired in type II pneumocytes isolated from 
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matrilysin-deficient mice as compared to cells isolated from wild-type animals. Although our results suggest that matrilysin 
plays a beneficial role in lung repair, it is possible that matrilysin activity produces pro-fibrotic molecules or that prolonged or 
excessive production of matrilysin may have deleterious effects on lung function. In any event, matrilysin is a key MMP 
expressed following lung injury, and understanding the mechanisms which regulate its expression and activity in the lung will 
be potentially important in the context of both normal lung repair and the pathogenesis of lung disease. 
Funded by grants from the National Institutes of Health, U.S.A. 
Differential expression of mucin (MUC) genes 1 and 5AC in 
airways of allergic rats 
A. K. RUSH, Y.-C. LILJ AND D. F. ROGERS 
Thoracic Medicine, National Heart & Lung Institute (Imperial College School of Medicine), Dovehouse Street, 
London S W3 6LY, U.K. 
The ovalbumin sensitized Brown Norway rat has pathophysiological features in common with human asthma, including 
increased IgE, bronchial hyper-responsiveness, increases in airway smooth muscle cell and epithelial cell DNA synthesis, and 
goblet cell hyperplasia. We used this model to investigate the effect of allergy on expression of rat mucin 1 (r MUCl), 
rMUC2 and rMUC5AC in trachea and lung. Rats were injected i.p. with 1 ml ovalbumin (1 mg) in saline (with 100 mg 
aluminium hydroxides as adjuvant) on days l-3. Control rats (sham sensitized) were injected with aluminium hydroxide in 
saline. On days 6, 9, 12, 15, 18 and 21 rats inhaled ovalbumin or saline (sham challenged). Tissues were collected for RNA 
extraction on days 1 (baseline), 5 (prior to first challenge), 7, 13, 19 and 22 (24 h after a challenge). Expression of each MUC 
gene was measured by semi-quantitative RT-PCR and quantified by densitometry as a ratio of rat GAPDH. Twenty four 
hours after the final challenge, rats sensitized and challenged with ovalbumin showed bronchial hyper-responsiveness (PC200 
acetylcholine: 2.2kO.04 mol l-‘, SEM; n= 3) compared with ovalbumin sensitization followed by saline challenge (P&00: 
1.6 f0.2 mol l-‘, n = 3). PCR showed that in both trachea and lung, sensitization followed by ovalbumin challenge 
significantly increased the expression of rMUCSAC, when compared with sham sensitized, ovalbumin challenged or 
sensitized and sham challenged groups (mean 3.6 k 0.5 arbitrary units, AU, vs. 0.5 f 0.2 AU and 0.1 f 0.1 AU respectively for 
trachea, day 19; 0.5 + 0.1 AU VS. 0.1) 0.1 AU and 0.1 f O,l AU respectively for lung, day 19; iz = 4-5). Sensitization followed 
by either sham or ovalbumin challenge significantly decreased the expression of rMUC1 in both trachea and lung when 
compared with the sham sensitized, ovalbumin challenged group (0.5 kO.06 AU and O-7&-0.12 AU vs. 1.9 iO.12 AU 
respectively for trachea, day 13; 0.9 + 0.14 AU and 1 ,O k 0.08 AU vs. 1.7 f 0.19 AU respectively for lung, day 13; IZ = 4-5). 
Signal for rMUC2 was not detected at any time point for trachea or lung, but was detected in small intestine (+ve control). 
No expression of rMUC1, 2 or 5AC was detected in heart (-ve control). We conclude that sensitization and repeated 
challenge of Brown Norway rats with ovalbumin results in differential expression of airway mucin genes, with rMUC5AC 
increasing and rMUC1 decreasing. 
Funded by Smithkline Beecham, King of Prussia, USA. 
Initial characterization of the human elafin gene promoter 
L. BINGLE*, T. D. TETLEY? AND C. D. BINGLE* 
*Division of Molecular and Genetic Medicine, University of Sheffield Medical School, Shefield and 
tDepartment of Respiratoy Medicine, Imperial College School of Medicine at NHL I, London, U.K. 
Elafin, a low molecular weight proteinase inhibitor is a member of the recently described trappin gene family, members of 
which are thought to play an important role in the regulation of inflammation. Previous studies by ourselves and others have 
shown constitutive expression of elafin mRNA from human type II cells, and after stimulation with either human neutrophil 
elastase, tumor necrosis factor (TNF) or interleukin-1 (IL-l), from lung epithelial cell lines A549, H322 and Beas-2B. Elafin is 
also constitutively expressed in normal mammary epithelial cells but differentially underexpressed in breast tumours (Zhang et 
al. Cancer Res. 57 46314636). In this study we will describe the basal and induced regulation of the elafin gene. Using PCR 
we generated four constructs from the promoter region of the human gene (-749, -505, -448 and -248), cloned into 
PGL3-luc and transiently transfected into two human lung epithelial cells lines, A549 (elafin expressing) and H441 (non- 
expressing). Reporter gene activity was quantitated by measuring luciferase activity (firefly) and normalized for transfection 
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efficiency following co-transfection with either beta-galactosidase or a second luciferase vector (Renilla). Basal expression of 
all constructs was higher in A549 cells than in H441 cells. 
The AP-1 site at position -477 has previously been shown to be crucial for expression in normal human mammary 
epithelial cells, this was not the case in the lung cells. Gene activity in the mammary cells was reduced to zero when the AP-1 
site was removed (cf -505 and -448) but only to 86% (A549) and 95% (H441) in the lung cells. Further reduction of 
construct size to -248 resulted in 48% and 65% activity compared with -505. 
We also attempted to stimulate the -749 construct using cytokines known to increase elafin mRNA levels in A549 cells, 
namely 20 ng ml- ’ TNF or IL-l, added 24 h after transfection. We were unable to produce such an effect in either cell type, 
suggesting that regions important for this regulation are located outside of the proximal promoter. 
Infection with recombinant adenovirus constructs-a tool for 
studying functions of cytokines and proteoglycans 
G. WESTERGREN-THORSSON”, B. S&NSTRAND */ ?, l? J. SIME~, J. GAULDIE? AND A. MALMSTR~M” 
*Dept. of Cell and Molecular Biology, Lund University, Lund, Sweden, +Dept. of Pharmacology, Pre-clinical 
R&D, Astra Draco AB, Lund, Sweden and $Dept. of Pathology, McMaster University, Hamilton, ON, Canada 
Pulmonary fibrosis is the ultimate outcome of many interstitial lung diseases, where the pathogenesis is poorly understood. 
Several studies have indicated that TGF-P a central role in this process. It is also well established that biglycan and decorin 
interacts and at least decorin abrogates the effect of TGF-B. To get information about a more precise role of these molecules 
in the process of development fibrosis rats were intracheally infected with lo9 pfu/animal of adenovirus containing cDNA for 
active- or latent TGF-b, biglycan or decorin. 
Infection with active adenovirus containing active TGF-PI, but not latent, resulted in 60-fold increase of mRNA level for 
TGF-l31 leading to a prolonged and severe interstitial and pleural fibrosis. This was characterized by an increased production 
of total proteoglycan and collagen with maximal increase of Z-fold after 21 days. Production of biglycan increased 2-fold 
between day 7 and 14 whereas decorin production decreased transiently during this time period. After 14 days decorin 
production started to increase, whereas biglycan production decreased to normal values again. Transfection of animals 
intracheally with adenovirus containing cDNA for biglycan (lo9 pfu/animal) resulted in a reversible type of fibrosis. The 
collagen and biglycan content increased 223 fold. Decorin decreased transiently at day 7 and 14. Transfection with adenovirus 
with cDNA for decorin did not result in fibrosis, only small effects were noted on connective tissue parameters. In conclusion, 
these results illustrate the role of TGF-l31 and the importance of its activation in the pulmonary fibrotic process. It also shows 
that proteoglycans, like biglycan can affect the outcome of this process. 
Grants from Swedish Medical Research Council and Swedish Heart-Lung Foundation. 
Characterization of human FKH-5: a SCLC restricted HNF-3 
forkhead transcription factor 
C. D. BINGLE* AND S. CASCIO? 
*Division of Molecular and Genetic Medicine, University of Sheffield Medical School, Sheffield U.K. and 
+Neurosurgery, Brown University, Providence, Xl, U.S.A. 
Expression of the HNF-3/forkhead family of transcription factors is widely distributed across a range of tissues, including the 
lung, where they have been proposed to play a role in the regulation of a number of lung specific genes. We have previously 
described the use of RT-PCR with degenerate primers to conserved regions of the HNF-3/forkhead family to identify partial 
cDNAs for HNF-3/forkhead proteins expressed in human lung cell lines. We now describe the isolation and characterization 
of the full length sequence of one of these partial clones, the human homologue of the murine brain enriched family member, 
fkh-5, from a SCLC line. fkh-5 has no identified molecular targets but is essential for normal brain function. Full length 
human fkh-5 was isolated by a combination of genomic and RT-PCR and codes for a protein of 324 amino acids which has 
two substitutions compared to the mouse protein and is also highly conserved with xenopus fkh-5 and zebra fish FKD3. The 
DNA binding domain of fkh-5 is at the N-terminal end of the protein and the C-terminal portion is rich in alanine, serine and 
proline (36%) and contains a proline repeat region which may a site of protein/protein interaction. Expression of mfkh-5 was 
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only found in NCl-H841 cells amongst > 20 lung lines tested. The complete fkh-5 gene is contained within a single 6Kb Eco RI 
fragment and the entire coding region is contained in a single exon with the only intron being found in the 5’ UTR. Transient 
transfection experiments with luciferase based reporter constructs suggest that the 5’ region of the gene contains a functional 
promoter element which is active in H841 cells. The identification of the nemoendocrine-like H841 cells as expressors of fkh-5 
suggest that such cells ifz situ within the lung may be sites of expression of this gene and furthermore should allow us to 
identify its molecular targets. 
Posters 
Lipid-peptide-DNA complexes as artificial virus-like 
particles for nebulization to the lung 
J. C. BIRCHALL*, E. J. COLLINS *, I. W. KELLAWAY*, J. L. RICHARDSON+ AND M. GUMBLETON* 
Welsh School of Pharmacy, Cardiff University, CFl 3XF and i- Pfizer Central Research Ltd, Sandwich, U.K. 
Jet nebulization is the most acceptable system for aerosolization of gene vectors. The physical stability of the gene during the 
aerosolization process is a determining issue; with high cationic lipid : pDNA mass ratios (i.e. 12 : 1 w/w DOTAP : pDNA) 
shown to be required to maintain pDNA integrity against physical shearing (Crook, et al. Gene Ther 1996: 3: 834-839). Pre- 
condensation of pDNA with polycationic peptides potentiates cationic liposome-mediated gene delivery (Gao, et al., Biochem 
1996: 35; 1027-1036). In this in vitro study, DOTAP : pDNA complexes and DOTAP : protamine : pDNA complexes were 
nebulized using a Pari LC Plus jet nebulizer and investigated for changes in complex diameter and structure and pDNA 
integrity. The process of jet nebulization adversely affected the physical stability of DOTAP : pDNA complexes with only those 
formulated at 12 : 1 w/w able to maintain their particle size distribution [ - 140 nm] and preserve a degree of pDNA integrity 
within the nebulizer reservior [35% retention of pre-nebulized DNA signal]. In contrast, DOTAP : protamine : pDNA integrity 
complexes (3 : 2 : 1 w/w ratios) were smaller [ - 100 nm] and more homogeneous, and preserved greater pDNA integrity [90% 
retention of pre-nebulized DNA signal]. To further progress the use of triplexes in inhalational gene therapy we investigated the 
use of pre-condensing peptides incorporating, as a contiguous part of the molecule, nuclear localization signals. Specifically, we 
investigated replacement of protamine by SV40 large T-antigen NLS (peptide sequence PKKKRKV). The SV40 NLS is 
comprised of 70% cationic residues compared to protamine with 66% of its 32 amino acid residues 
cationic. However, the SV40 NLS showed only poor ability to condense pDNA, i.e. excluding only 50% EtBr intercala- 
tion with pDNA, even at a charge (+/-) ratio of 20 : 1, while protamine (at a charge (+/-) ratio of 1.5 : 1) excluded 
95% EtBr intercalation; the EtBr displacement data being consistent with Dnase 1 protection assays comparing 
SV40 NLS and protamine. Work is continuing with examination, by microinjection and cell transfection, of the relative role 
of NLS vs. nuclease protection functionalities in the ‘precondensing’ peptide component of triplex systems for lung inhalation. 
High efficiency of gene transfer to human airway epithelial 
cells with LID vector containing integrin-targeting peptide 
O-H. MENG*, C. KINNON*, R. MCANULTY? AND S. HART* 
“Molecular Immunology Unit, Institute of Child Health, University College London, London WCIN 1 EN and 
+Centve for Cardiopulmonary Biochemistry and Respirato y Medicine, The Rayne Institute, University College 
London, London WClE 6JJ U.K. 
We have developed a non-viral, receptor-mediated vector, lipofectin/ integrin-targeting peptide/DNA (LID) complex, for 
gene therapy. With the aim of applying this vector to the therapy of human respiratory diseases, we have now assessed its use 
in human airway epithelial cells from normal and cystic fibrosis (CF) lung. The LID complex used in this study consisted of 
peptide 6 (pep6, [K]i6 GACRRETAWACG which binds integrin ~501) and plasmid DNA, incorporated with lipofectin. The 
cells were transfected with several different reporter genes including luciferase gene (pGL3-Luc), P-galactosidase gene (pCIK- 
PGal) and green fluorescent protein gene (pEGFP). The effects of electrical charge ratio peptide to DNA on the efficiency of 
transfection were assessed at a range of 1 : 1 to 10 : 1 ratio. High efficiency was observed from 3 : 1 to 8 : 1 ratio. The levels of 
luciferase activities in cell lysates from normal and CF cells transfected with pGL3-Luc were 770550 (RLU per mg protein) 
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and 835690 at 3 : 1 ratio, 835220 and 692280 at 7 : 1 ratio, respectively. Similar results were observed with another reporter 
gene, p-galactosidase, as detected by histochemical X-Gal staining. A large proportion of both normal and CF cells exhibited 
P-galactosidase activities as evident by the dark blue staining with X-Gal reagents. The overall efficiency of LID transfection 
was assessed by FACS analysis after transfecting the cells with pEGFP reporter gene. Among 10 000 cells analysed, 43% of 
normal cells and 55% of CF cells were positive for GFP fluorescence, respectively. However, the transfection was inefficient 
when the cells grew to complete confluence and particularly, when transfecting the primary bronchial epithelial cells growing 
from explants. To increase the transfection efficiency in this case, we tested the effects of pre-incubation of the cells with a 
monoclonal antibody against human E-Cadhrin, a molecular involved in the formation of gap junction between cells. After 
incubation with anti-cadhrin, transfection efficiency as expressed by luciferase activity (RLU/mg protein), increased IO-fold in 
confluent normal cells and 5-fold in primary bronchial epithilial cells from a patient with pulmonary hypertension. In 
summary, LID complex transfects human airway epithelial cells with high efficiency and may provide a potential vector to 
transfer genes to human lung epithelium for therapy of respiratory diseases. 
(This work was supported by British Lung Foundation) 
Transcriptional regulation of thyroid transcription factor-l (TTF-1) 
I. L. WHITEHOUSE” Y. C. LEE? C. D. BINGLE~, M. ANTONIOU AND G. SANTS* 
*Department of Respiratory Medicine and Experimental Pathology, Guy‘s Hospital, London SE1 9RT, U.K. 
+Department of Internal Medicine, Chonbuk University, S. Korea $Division of Molecular and Genetic Medicine, 
University of Sheffield Medical School Sheffield SIO 2JF, U.K. 
TTF-1 is a regulator of lung-specific genes such as surfactant proteins A, B and C and Clara cell secretory protein. It is also 
vital for the normal development of the lungs, thyroid and parts of the forebrain. TTF-1 gene knockout mice die at birth with 
primitive lung buds containing no differentiated epithelium. 
The aim of this work is to investigate the transcriptional regulation of the TTF-1 gene in particular high order regulatory 
sequences distal to the proximal promoter. DNase I hypersensitive (HS) sites represent a marker for open and potentially 
active chromatin and are likely to be of particular importance in gene regulation, being associated with many DNA sequences 
that regulate gene expression. 
We have performed DNase I hypersensitivity assays to locate HS sites in a 24kb DNA region containing the 3kb TTF-1 
gene. Five DNase 1 HS sites have been identified. There is one intragenic site and four sites upstream of the TTF-I 
transcription start site. Transgenic mice have been generated using a 70kb subclone of a 120kb CYPAC clone containing the 
human TTF-1 gene. Transgenic status was confirmed by PCR on tail DNA and Southern bolts, using a TTF-1 probe. RNA 
expression of the TTF-1 transgene was detected by RT-PCR with a radiolabelled PCR primer. Human TTF-1 was expressed 
in the lungs and brains of adult transgenic mice. 
The functional significance of the HS sites will be assessed in cell culture and transgenic animal systems. If the identified 
control elements could be condensed into a suitable gene delivery vector, such as those based on adenoviruses, the system 
could potentially provide the mechanism for regulated, lung-specific gene expression for gene therapy purposes. 
Profiling changes in fibroblast gene expression induced by 
TGFPl using oligonucleotide Genechip technology 
R. C. CHAMBERS*, J. ALLARD? C. LOCK?, H. VAN WART?, G. J. LAUREN* D. WEMBRIDGE* AND 
R. HELLEL~ 
“Centre for cardiopulmona y Biochemistry and Respirato y Medicine, Royal Free and University College Medical 
School, Rayne Institute, London WCZE 6JJ, U.K. and tInfl’ammatory Diseases Unit, Roche Bioscience, Palo Alto, 
CA, U.S.A. 
The recent emergence of oligonucleotide microarray technology offers the promise for the simultaneous monitoring of the 
expression of thousands of genes. In order to evaluate the usefulness of this technology for profiling changes in gene expression 
patterns in pulmonary fibrosis, we designed a 25-mer oligonucleotide microarray chip containing 60 sequences which represent 
a perfect match and a corresponding number of mismatch sequences for 500 genes of interest, arrayed onto 1.5 cm2 glass slides 
by a combination of photolithography and oligonucleotide chemistry (in conjunction with Affymetrix, Santa Clara). In this 
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study, we report the changes in gene expression obtained for a subset of genes for human foetal lung frbroblasts exposed to the 
prototypical pro-fibrotic mediator, TGFP,. RNA preparation for hybridization was performed according to protocols supplied 
by Affymetrix (Lockhart et al. 1996, Nature Biotechnology 14: 1675-1680). Of the 2X2 human genes profiled, there was a one 
and a half-fold increase in gene expression for 30 individual genes across all functional gene classes. Of these genes, 13 were 
matrix or matrix-modulating genes, and included the genes encoding the alpha 1 chains of procollagen I and III which were 
maximally increased by 6.0 and 2.4-fold, as well as the genes encoding elastin, fibronectin and biglycan, which were maximally 
increased by 13.7, 2.8 and 2.3-fold, respectively. These findings are consistent with published data for fibroblasts exposed to 
TGFfii by conventional single gene analysis methods and demonstrate that olingonucleotide microarrays offer a unique 
oppurtunity for profiling changes in gene expression patterns in response to pro-fibrotic mediators. This approach is likely to be 
invaluable for improving our understanding of the molecular mechanisms by which known and novel pro-fibrotic mediators 
exert their cellular effects and should be readily applicable for profiling human lung tissue. 
This research was supported by The Wellcome Trust and Roche Bioscience. 
Early events in the response to phosgene exposure of human 
lung cells grown at the air-liquid interface 
G. PHILLIPS, S. HIBBS AND N. HUGHES 
Biomedical Sciences Department, DERA Portion Down, Salisbury, Wiltskire SP4 OJQ, U.K. 
Cell culture techniques have been used extensively and successfully at CBD Porton Down to identify and screen potential 
cytoprotectant compounds for use against inhaled toxicants. Current techniques routinely use cell lines that are grown while 
submerged under culture medium. There is therefore a requirement for a model that will allow cells to be grown and exposed to 
gases at the air-liquid interface, a model which more closely resembles in vivo conditions. Phosgene (CG), a reactive oxidizing 
gas, is used as a chemical intermediate for the production of a variety of industrial products. Exposure to CG leads to the 
development of life threatening oedema. However the early mechanistic events of tissue injury by CG are not fully understood. 
Our aim was to develop a model to study the response of human lung cells exposed to gases at the air-liquid interface and to 
investigate the early events in tissue injury following exposure to CC. 
Cell lines derived from human pulmonary (A549), bronchial (BEAS-2B) and nasal (RPMI-2650) epithelium were initially plated 
onto microporous membranes coated with collagen/fibronectin and growth submerged for 24 h. Cells were then raised to the air- 
liquid interface by removal of the covering medium and cultured for a further 6 days. On day 7 the membranes were placed in a 
closed, air-tight chamber to which CG was added. Cells were then exposed for 10 min to a range of CG concentrations. Control 
cells were exposed to air for the same length of time. The membranes were then removed and the cells allowed to recover for up to 
3 h. Cells were taken for biochemical and morphological analysis at 0, 60 and 180 min following CG exposure. 
Microscopic examination of all three cell lines revealed evidence of necrotic cell damage immediately following CG 
exposure. This was supported by an 800% increase in lactate dehydrogenase activity, a marker of cell injury, in the culture 
medium below the cells and a 40% decrease in cellular viability as measured by the MTT assay. 
The growth of pulmonary cells at the air-liquid interface allows the exposure of lung cells to CG and other toxic gases. 
Exposure to CG results in early cell injury and further studies are under way to elucidate the mechanism involved in this type 
of injury. This model more closely resembles in vivo conditions, may aid in the development of medial countermeasures 
against the action of inhaled toxins and supports the requirements for a reduction in whole animal studies. 
Steroid pretreatment prevents neutrophil recruitment 
but does not alter lung antioxidant status 
during cardiopulmonary bypass 
A. WILLIAMS*, F. J. KELLY*, A. WIELAGORSKY~ AND R. M. LEACH? 
*Cardiovascular Research and ‘Department of Intensive Care, St Thomas Hospital, London, SE1 7EH, U.K. 
Cardiopulmonary bypass (CPB) is often associated with the development of acute lung injury. This is thought to arise in part 
through interleukin-8 (IL-Q production and the recruitment of neutrophils to the lung. Activated neutrophils release reactive 
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oxygen species, increasing the oxidative burden in the lung and potentially impacting on the local antioxidant status. Steroid 
pretreatment reduces the incidence of post-traumatic acute lung injury in animal models. In this study we examined the 
hypothesis that steroid pretreatment would blunt the cytokine response, decrease neutrophil recruitment and enhance 
antioxidant status in the lungs of CPB patients. Bronchoalveolar lavage (BAL) was performed on 14 patients prior to CPB 
and at 0 and 4 h post surgery. Preoperative steroids (dexamethasone 25-100 mg) were given to six of the patients. BAL fluid 
IL-8 concentration was determined using ELISA. The water soluble antioxidants, ascorbate and urate, were measured using 
HPLC. Differential cell counts were also performed 
Parameter Treatment Pre Oh 4h 












41 (13, 93) 
62 (23, 220) 
4 (2, 6) 
3 (1, 3) 
1.3 (0.9, 1.7) 
1.7 (1.2, 2.6) 
1.0 (0.6, 2.4) 
0.7 (0.6, 1.1) 
458 (222, 980) 
121 (7, 240)” 
21 (14, 60)+ 
3 (3, 30) 
1.2 (1.0, 2.1) 
1.3 (1.1, 1.6) 
4.7 (2.2, 9.8)+ 
1.5 (1.0, 6.9)+ 
467 (192, 699) 
137 (67, 344)” 
32 (20, 40)+ 
11 (3, 32) 
1.1 (1.0,1.3) 
1.5 (1.4, 2.5) 
3.5 (1.2, 6.4)+ 
9.6 (1.7, 14.4)+ 
Data are presented as median (25th , 75th percentile). *represents P< 0.05 compared to the non-steroid control using Mann 
Whitney U test +represents a P< 0.05 compared to the pre surgery control using surgery control using Kruskal Wallis 
ANOVA. Steroid pretreatment was found to diminish the increase in IL-8 and neutrophils in the lungs following CPB, but 
antioxidant status remained unchanged. This suggests that neutrophilia alone is not responsible for the increase in urate seen 
during CPB. 
The effect of phosphodiesterase inhibitors on the response of 
rat lungs to hypothermic storage 
R. I. FEATHERSTONE”, F. J. KELLY~ AND D. J. CHAMBERS* 
*Cardiac Surgical and iCardiovascular Research, The Rayne Institute, St Thomas’ Hospital, London SE1 7EH, 
U.K. 
Raising intracellular CAMP or cGMP levels using phosphodiesterase (PDE) inhibitors can protect the lungs against 
ischaemia-reperfusion injury (Pinsky D.J., Thrombosis & Haemostasis 1995: 74; 58-65). We compared the effect of 
selective PDE type III (Milrinone), IV (Rolipram), or V (Zaprinast) inhibitors (as additives to St. Thomas’ Hospital 
solution (STH) used for hypothermic flushing and storage of lungs) on functional protection and their ability to 
increase cyclic nucleotide levels. Rat lungs were excised, perfused via the pulmonary artery with deoxygenated 
bicarbonate buffer containing rat blood (4: 1, v/v) and ventilated. Compliance (tidal volume to tracheal pressure ratio) 
and gas exchange (difference in pOz of perfusate entering and leaving the lung) were measured. After 20 min control 
perfusion, lungs were flushed with cold (4°C) STH or STH plus PDE inhibitor and immersed in the same solution for 8 
h. After storage, lungs were either immediately frozen for later assay of cyclic nucleotides or reperfused for 40 min 
(37°C) to assess recovery of function. Cyclic nucleotide levels (pmoles mgg’ protein) after storage and compliance (ml 
cmHzO- ‘) and g as exchange (A02, mmHg) after the reperfusion period are shown below. Data for unstored lungs are 
shown for comparison. 
Hypothermic storage caused a significant decline in CAMP but not cGMP. Increases in post storage CAMP by Milrinone or 
cGMP by Zaprinast did not lead to improvement in functional parameters. Of the inhibitors studied, only Rolipram 
attenuated the adverse effects of storage on compliance and gas exchange in addition to preventing the storage-induced fall in 
CAMP levels. 
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Experimental Group Compliance Gas Exchange CAMP cGMP 
Unstored 
STH 
STH+ 100 PM Milrinone 
STH-tlOO PM Rolipram 
STHflOO PM Zaprinast 
0.20 f 0,02* 46.6f2.F 26.4+ 7.7” &Of- 1.0 
0.08 kO.01 4.7k2.2 13.Ok3.7 7.8fl.l 
0~11+0~03 ll.OIfr6.2 29.Ok2.5” 7.8f3.1 
0.19f0.03” 20.7$4.9* 44.12 5.3” 6.550.5 
0~10~0~01 9.1 i4.6 14.924.1 14.5i2.4 
Mean (k SE) of 5-6 observations. 
*P-co.05 compared to lungs stored 8 h in STH (Student-Newman-Keul’s test). 
Expression of aspartic proteinase genes in human alveolar 
macrophages and in healthy lung and lung tumours 
M. COOK*, F. B~~HLING?, S. ANSORGE?, J. KAY* AND P. J. TATNELL* 
*School of Biosciences, Cardiff University, Cardiff, CFl 3US, Wales, U.K. 
bzstitut fir Experimentelle Innere Medizin, Otto-von-Guericke-Universitiit, O-39120 Magdebuvg, Gevmany 
Cathepsin D is present in the lysosomes of most human cells, whereas cathepsin E and the recently discovered aspartic 
proteinase, napsin, have a more restricted tissue and cellular distribution. The expression of the genes encoding each of these 
enzymes was examined in morphologically normal and cancerous regions of the human lung by quantifying the levels of each 
mRNA transcript. The mRNA levels in alveolar macrophages isolated from bronchoalveolar lavage were also examined. 
RNA was isolated from each tissue biopsy/cell sample and reverse transcribed into cDNA using random hexamer primers. 
For each of the three gene transcripts, specific oligonucleotide primers were used in quantitative polymerase chain reactions 
which enables the amplicon formation to be monitored by measuring the fluorescence change resulting from the intercalation 
of Sybr Green into increasing amounts of DNA being generated. The amount of each mRNA (as cDNA equivalents) was 
quantified and is depicted as a ratio relative to that of cathepsin D, set at 1.00, since this enzyme is considered to be the 
product of a housekeeping gene. 
Sample Cathepsin D Cathepsin E Napsin 
Macrophages 1 0 0.01 
Normal Lung 1 0.06 0.03 
Lung Tumour 1 0.10 0.03 
The cathepsin E gene was not expressed in alveolar macrophages. Comparable levels of cathepsin E and napsin transcripts 
were detected in healthy lung biopsies, with the amount of cathepsin D mRNA being considerably higher. These relative 
amounts did not change significantly in the lung tumours analysed. 
